Subcutaneous Biologics Market: Moving Towards a Brighter Future

Image Credit : openpr

Biologic, also known as biopharmaceutical, is a complex medicinal product manufactured by a biological process. Examples of biologics include blood and plasma derived products, vaccines, somatic cells and body proteins. Biologics market refers to a multibillion dollar opportunity that is expanding globally at an impressive growth rate. Most biologic products are given intravenously. However, in the past few years, a number of biologics have been developed that are given subcutaneously. The subcutaneous route of administration offers significant advantages over intravenous administration such as ease of drug administration, does not require skilled personnel for drug administration, enables at-home drug delivery and thus reduces patient time at healthcare facilities, reduced medicine cost and increased therapy compliance. Owing to aforementioned factors, the subcutaneous route of administration has gained enormous traction in recent years. Subcutaneous route of drug administration are highly effective in administering biologics such as vaccines, proteins, peptides, antibodies and other large and complex molecules.

To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/74

Increase in Awareness and the number of Diagnosed cases will Drive Demand in Developing Regions

In terms of geography, the global market for subcutaneous biologics is segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). There is huge healthcare spending in countries such as United States and Canada, and high prevalence of diseases such as rheumatoid arthritis and breast cancer. The Centers for Disease Control and Prevention (CDC) estimate that the current prevalence of rheumatoid arthritis (nearly 50 million Americans in 2012) will increase to 78 million by 2040. The disease also affects nearly 300,000 children in the U.S. according to RheumatoidArthritis.org. In the European region, EU-5 countries (Germany, France, United Kingdom, Italy and Spain) are the most potential market owing well established economy of these regions. Convenient drug delivery format is also in demand in developing regions such as Asia Pacific and Latin America where therapy compliance is a major issue. Large undiagnosed population, inadequate access to medicines and affordability issues hinder the market growth for subcutaneous biologics in developing regions.

The global market for subcutaneous biologics will be expanding under the influence of factors such as:

Advantages over other routes of administration

Increasing trend of self-medication

Introduction of innovative drug delivery devices such as auto-injectors and prefilled syringes

Growing incidence and prevalence of rheumatoid arthritis and breast cancer

Growth in the biosimilars market

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/74

Some of the major companies operating in the global subcutaneous biologics market include Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG, Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd. and Bristol-Myers Squibb.

You may be interested

Increasing funding in gene therapies is expected to fuel the growth of viral vectors and plasmid DNA manufacturing market
Healthcare
Healthcare

Increasing funding in gene therapies is expected to fuel the growth of viral vectors and plasmid DNA manufacturing market

Albert R - April 25, 2018

Gene therapy and genetically modified therapies are promising treatment option, which includes introduction of a normal or functional copy of a gene in the defective cell. Gene…

Increasing incidence of cancer is expected to fuel the growth of cancer metabolism based therapeutics market
Healthcare
Healthcare

Increasing incidence of cancer is expected to fuel the growth of cancer metabolism based therapeutics market

Albert R - April 25, 2018

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to…

Innovation in technology to combat infectious diseases is expected to drive the future meningitis treatment market
Healthcare
Healthcare

Innovation in technology to combat infectious diseases is expected to drive the future meningitis treatment market

Albert R - April 25, 2018

Major driving factor for growth of the meningitis treatment market include the alliance of public and private sectors to increase availability of vaccine to the populace. For…

Most from this category